EUCTR2008-007338-23-IS进行中（未招募）不适用
A phase II, randomized, double-blind, placebo and active controlled, parallel group, multi-center, dose ranging study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in patients with resistant hypertension.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. An established diagnosis of hypertension with MSSBP > 140mmHg and < 180 mmHg on current antihypertensive treatment measured within two (2) weeks of randomization. This includes subjects with diabetes and/or chronic kidney disease.
- •2. Resistant hypertension as defined by the failure to achieve goal blood pressure in patients who are adhering to optimal doses of a stable three-drug regimen that includes a diuretic for a period of at least 4 weeks.
- •3. Male or non-fertile female patients 18 to 75 years of age (inclusive)
- •o Female subjects must have been surgically sterilized (oophorectomy with or without hysterectomy) at least 6 months prior to screening. Surgical sterilization procedures must be supported with clinical documentation made available to sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF.
- •o Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion. Menopause will be confirmed by a plasma FSH level of =40 IU/L
- •o Male subjects must be using a double-barrier local contraception, i.e., spermicidal gel plus condom, for the entire duration of the study, up to Study Completion visit, and refrain from fathering a child or donating sperm in the three (3) months following last study drug administration.
- •4. Morning plasma cortisol (sampled between 08:00 and 09:00) > 250 nM
- •5. Able to provide written informed consent prior to study participation.
- •6. Able to communicate with the investigator and willing to comply with the requirements of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •For full list, please refer to the protocol.
- •1. Severe hypertension (MSSBP > 180 mmHg or MSDBP > 110 mmHg) at screening.
- •2. Pregnant or nursing (lactating) women, where pregnancy confirmed by a positive hCG laboratory test (>5 mIU/ml).
- •3. Recent history (within last 6 months) of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack (TIA).
- •4. Clinically significant cardiac conduction defects (eg, 3rd degree atrioventricular [AV] block, left bundle branch block [LBBB], sick sinus syndrome, atrial fibrillation or flutter).
- •5. Implanted cardioverter defibrillator (ICD) that has fired for any arrhythmia within 3 months of screening or implanted pacemakers.
- •6. Clinically significant valvular heart disease.
- •7. A history of secondary hypertension of any etiology (eg, renal parenchymal hypertension, renovascular hypertension, coarctation of the aorta, primary hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing’s disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension, obstructive sleep apnea, etc).
- •8. Known moderate or maliganant retinopathy defined as: moderate (retinal signs of hemorrahage, microaneurysm, cotton-wool spots, hard exudates, or a combination thereof) or maliganant (signs of moderate retinopathy plus swelling of the optic disk).
- •9. Type 1 diabetes.
- •10. Type 2 diabetes mellitus with poor glucose control as defined by HbA1c >9%.
研究者
相似试验
进行中（未招募）
2 期
Phase II, double-blind, randomized, placebo-controlled, multicentre study to evaluate the safety, efficacy, and pharmacokinetics of TAK-242 and Granulocyte Colony-Stimulating Factor (G-CSF) (G-TAK) in subjects with severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF)Alcoholic hepatitisSevere alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF)Digestive SystemISRCTN36798599Yaqrit Ltd78
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of study drug (sepranolone) in patients with premenstrual dysphoric disorder (PMDD)Premenstrual dysphoric disorder (PMDD)MedDRA version: 20.0Level: PTClassification code 10051537Term: Premenstrual dysphoric disorderSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2017-000822-37-GBAsarina Pharma250
进行中（未招募）
1 期
This is a Phase 2 randomized, double-blind study to determine the safety and efficacy of Reltecimod as compared to placebo in patients who have acute kidney injury due to an intra-abddominal infection causing sepsis in which all patients receive usual standard of care treatment for their infection.EUCTR2018-002547-29-FRAtox Bio120
进行中（未招募）
1 期
This is a Phase 2 randomized, double-blind study to determine the safety and efficacy of Reltecimod as compared to placebo in patients who have acute kidney injury due to an intra-abddominal infection causing sepsis in which all patients receive usual standard of care treatment for their infection.Acute kidney injury due to intra-abdominal infection/sepsisMedDRA version: 20.1Level: LLTClassification code 10080269Term: Stage 2 acute kidney injurySystem Organ Class: 100000004857MedDRA version: 20.1Level: LLTClassification code 10080271Term: Stage 3 acute kidney injurySystem Organ Class: 100000004857MedDRA version: 20.1Level: LLTClassification code 10079983Term: Complicated intra-abdominal infectionSystem Organ Class: 100000004862MedDRA version: 20.0Level: LLTClassification code 10040050Term: Sepsis NOSSystem Organ Class: 100000004862EUCTR2018-002547-29-BEAtox Bio120
进行中（未招募）
1 期
This is a Phase 2 randomized, double-blind study to determine the safety and efficacy of Reltecimod as compared to placebo in patients who have acute kidney injury due to an intra-abddominal infection causing sepsis in which all patients receive usual standard of care treatment for their infection.EUCTR2018-002547-29-NLAtox Bio120